Legal & General Group Plc Decreases Position in HCA Healthcare, Inc. $HCA

Legal & General Group Plc lessened its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 2.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,116,033 shares of the company’s stock after selling 27,138 shares during the quarter. Legal & General Group Plc owned approximately 0.48% of HCA Healthcare worth $427,552,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Nuveen LLC purchased a new stake in HCA Healthcare in the 1st quarter valued at approximately $569,217,000. Pacer Advisors Inc. increased its position in HCA Healthcare by 6,237.9% during the 1st quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock worth $466,815,000 after purchasing an additional 1,329,618 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in HCA Healthcare by 83.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock valued at $829,104,000 after purchasing an additional 1,091,416 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of HCA Healthcare by 49.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock worth $615,583,000 after buying an additional 587,036 shares in the last quarter. Finally, Abdiel Capital Advisors LP acquired a new stake in HCA Healthcare during the first quarter worth approximately $164,835,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

Insider Transactions at HCA Healthcare

In related news, EVP Michael R. Mcalevey sold 3,892 shares of the business’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total value of $1,843,990.68. Following the transaction, the executive vice president owned 3,487 shares in the company, valued at approximately $1,652,105.73. The trade was a 52.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the sale, the executive vice president owned 31,503 shares in the company, valued at $13,194,716.52. This represents a 10.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on HCA shares. Wells Fargo & Company lifted their price objective on HCA Healthcare from $412.00 to $431.00 and gave the company an “equal weight” rating in a research report on Thursday, November 13th. Oppenheimer upped their price objective on shares of HCA Healthcare from $400.00 to $500.00 and gave the company an “outperform” rating in a research note on Monday, October 27th. Raymond James Financial set a $525.00 target price on shares of HCA Healthcare in a report on Monday, October 27th. Truist Financial boosted their price objective on shares of HCA Healthcare from $460.00 to $495.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Finally, Zacks Research upgraded HCA Healthcare from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $474.53.

HCA Healthcare Price Performance

Shares of HCA opened at $491.41 on Friday. The stock has a market cap of $112.14 billion, a PE ratio of 19.00, a P/E/G ratio of 1.38 and a beta of 1.41. HCA Healthcare, Inc. has a 12 month low of $289.98 and a 12 month high of $493.80. The stock’s 50-day moving average is $440.98 and its two-hundred day moving average is $400.78.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Friday, October 24th. The company reported $6.96 EPS for the quarter, topping the consensus estimate of $5.64 by $1.32. The firm had revenue of $19.16 billion for the quarter, compared to analyst estimates of $18.55 billion. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.HCA Healthcare’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the company posted $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. On average, research analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be issued a $0.72 dividend. The ex-dividend date is Monday, December 15th. This represents a $2.88 dividend on an annualized basis and a yield of 0.6%. HCA Healthcare’s payout ratio is currently 11.13%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.